Abstract: The present invention relates to a method of stabilizing and/or isolating nucleic acids, wherein a biological sample containing nucleic acids is contacted with a cationic compound. The invention also relates to said cationic compound per se and to the use of said cationic compound in stabilizing and/or isolating nucleic acids. Furthermore, the invention relates to pharmaceutical compositions, diagnostic compositions, and to compositions used in research, which include cationic compounds or a complex being formed upon contact of said cationic compound with a nucleic acid.

Abstract: The present invention is related to a method for isolating a target nucleic acid from a sample comprising said target nucleic acid, comprising the steps of mixing a sample containing said target nucleic acid with a binding solution and a nucleic acid binding matrix, binding at least part of said target nucleic acid to said nucleic acid binding matrix, wherein said nucleic acid binding matrix is treated simultaneously or has been previously treated with at least one compound comprising a metal substance selected from the group consisting of metals of the main groups 13 to 16, semimetals and transition metals for reducing non-target nucleic acid contaminations or wherein said nucleic acid binding matrix is modified with hydrophobic groups. Furthermore, respective kits and reagents are provided with the teaching of the present invention.

Abstract: The present invention relates to a device and a method for normalising nucleic acid concentrations, preferably for normalising nucleic acid concentrations in enzymatic nucleic acid amplification and modification methods.

Abstract: The present invention concerns new monolithic shaped bodies, a method for their preparation as well as their use especially for the selective purification and separation of biopolymers. A chromatographic separation material is provided with the new monolithic shaped bodies that allows a selective, efficient and reproducible purification and separation of biopolymers.

Abstract: The present in invention relates to a method for the separation of living cells from a mixture of dead and living cells which optionally can also possibly contain cell fragments.

Abstract: The present invention relates to an improved method for isolating nucleic acids, particularly genomic desoxyribonucleic acid (DNA) from blood.

Abstract: The invention relates to a method for incorporation of a biomolecule into a cell including the method steps: i) production of a complex from a biomolecule, preferably a nucleic acid and a polymer which may be obtained by reaction of an amine monomer having at least two amine groups with an epoxide monomer having at least two epoxide groups and ii) incorporation of the biomolecule into a cell bx bringing the cell into contact with the complex. The invention further relates to the transformed cell obtained by said method, the use of a particular polymer for incorporation of a biomolecule into a cell, a kit for incorporation of a biomolecule into a cell, the use of said kit, a complex made from a biomolecule and a polymer, a therapeutic composition, the use of a complex of a biomolecule and a polymer for therapeutic treatment of the human or animal being and a method for treatment of a disease by means of gene therapy.

Abstract: The present invention provides copolymers that facilitate nucleic acid analysis, compositions that comprise such copolymers, and methods for making or using such copolymers.

Abstract: The present invention relates to processes for the targeted transfection of cells, compositions which may be used for such processes, and corresponding pharmaceutical compositions for gene therapy. In particular, the invention relates to a process for introducing nucleic acid into cells comprising the steps of (a) mixing a nucleic acid with a dendrimer, in which a proportion of the dendrimer molecules are biotinylated; (b) mixing the resulting complex of nucleic acid and dendrimer with a second complex consisting of avidin or streptavidin and a biotinylated target-specific binding molecule; and (c) incubating the complex formed in step (b) with cells. Dendrimers which are well suited to the present invention include, for example, partially solvolysed polyamidoamine (PAMAM) dendrimers. Target-specific binding molecules are, in particular, cell-type-specific markers of the cell surface of the target cells.

Abstract: Cationic cytofectins and liposomes comprising the same are disclosed which are especially useful for delivering exogenous compounds into cells in vitro and in vivo. The liposomes may comprise (a) a neutral lipid such as dioleoylphosphatidyl-ethanolamine (DOPE) or similar lipid-like compounds such as 1,2-dioleoyl-oxiphosphatidylethanolamine or other lipid-like structures and (b) one or more of the cationic cytofectins provided herein. The invention provides transfection kits and methods for delivery of exogenous compounds into cells.

Abstract: Cationic cytofectins and liposomes comprising the same are disclosed which are especially useful for delivering exogenous compounds into cells in vitro and in vivo. The liposomes may comprise (a) a neutral lipid such as dioleoylphosphatidyl-ethanolamine (DOPE) or similar lipid-like compounds such as 1,2-dioleoyl-oxiphosphatidylethanolamine or other lipid-like structures and (b) one or more of the cationic cytofectins provided herein. The invention provides transfection kits and methods for delivery of exogenous compounds into cells.

Abstract: The invention concerns an anion-exchange resin and its use as a polymeric anion-exchange agent in chromatographic procedures, especially for the purification and isolation of nucleic acids, as well as a chromatographic procedure, especially for the purification and isolation of nucleic acids.

Abstract: The present invention relates to processes for the targeted transfection of cells, compositions which may be used for such processes, and corresponding pharmaceutical compositions for gene therapy. In particular, the invention relates to a process for introducing nucleic acid into cells comprising the steps of (a) mixing a nucleic acid with a dendrimer, in which a proportion of the dendrimer molecules are biotinylated; (b) mixing the resulting complex of nucleic acid and dendrimer with a second complex consisting of avidin or streptavidin and a biotinylated target-specific binding molecule; and (c) incubating the complex formed in step (b) with cells. Dendrimers which are well suited to the present invention include, for example, partially solvolysed polyamidoamine (PAMAM) dendrimers. Target-specific binding molecules are, in particular, cell-type-specific markers of the cell surface of the target cells.

Abstract: Cationic cytofectins and liposomes comprising the same are disclosed which are especially useful for delivering exogenous compounds into cells in vitro and in vivo. The liposomes may comprise (a) a neutral lipid such as dioleoylphosphatidyl-ethanolamine (DOPE) or similar lipid-like compounds such as 1,2-dioleoyl-oxiphosphatidylethanolamine or other lipid-like structures and (b) one or more of the cationic cytofectins provided herein. The invention provides transfection kits and methods for delivery of exogenous compounds into cells.